Cancer is a heterogeneous disease driven by somatic mutations accumulating within a cell's genome.  Advances in high-throughput sequencing technologies have revolutionized our understanding of the genetic landscape of cancer, revealing intricate patterns of driver mutations, copy number variations, and epigenetic alterations unique to each tumor. This wealth of genomic data underpins the burgeoning field of personalized oncology.  Identifying specific driver mutations allows for the targeted selection of therapies, such as tyrosine kinase inhibitors for EGFR-mutated lung cancer, significantly improving treatment efficacy and minimizing adverse effects compared to conventional chemotherapies.  Furthermore, the integration of genomic data with clinical characteristics enables the stratification of patients into risk groups, facilitating the prediction of treatment response and prognosis.  Challenges remain, including the identification of actionable mutations, the complexities of tumor heterogeneity and evolution, and the cost-effectiveness of comprehensive genomic profiling.  However, ongoing research focusing on liquid biopsies, improved bioinformatics tools, and the development of novel targeted therapies promises to further refine personalized cancer medicine, paving the way for improved patient outcomes and a paradigm shift in cancer treatment strategies.